Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!
Merck and Ariad to team no new cancer drug
Posted Jul 13th 2007 6:01PM by Brian White
Filed under: Drug, All Cancers
It appears pharmaceutical giant Merck is wanting to get a larger piece of the cancer drug pie. The company iaspartnering with Ariad Pharmaceuticals
to develop a new cancer treatment (in an experimental stage) with the potential to make the smaller Ariad over a billion greenbacks.
Genentech's Avastin has
been selling like hotcakes lately, and the world is sure to see a slew of new-generation cancer drugs by 2010 if my crystal ball is correct. Right now, Ariad's experimental cancer drug -- known as 'AP23573' -- is helping define a new category of cancer drugs that block certain proteins and effectively "starve" cancer cells.
To the delight of both Ariad and Merck, AP23573 is on "fast track" mode for a quicker review (and most likely, approval) and it's also been set at a status by the FDA which promotes treatments for rare diseases.
Tags: Ariad, cancer drug, CancerDrug, Merck
Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.
When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.
To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br> tags.
